Related references
Note: Only part of the references are listed.Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome
Annette M. Lim et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
Karen E. Sheppard et al.
CLINICAL CANCER RESEARCH (2013)
Targeting cell cycle and hormone receptor pathways in cancer
C. E. S. Comstock et al.
ONCOGENE (2013)
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
John P. Leonard et al.
BLOOD (2012)
Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors
Jeffry L. Dean et al.
CELL CYCLE (2012)
A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma
Ken Dutton-Regester et al.
MOLECULAR CANCER THERAPEUTICS (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
Gottfried E. Konecny et al.
CLINICAL CANCER RESEARCH (2011)
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2011)
Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma
Bianca Devitt et al.
PIGMENT CELL & MELANOMA RESEARCH (2011)
Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
Karine Michaud et al.
CANCER RESEARCH (2010)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
The Association between MC1R Genotype and BRAF Mutation Status in Cutaneous Melanoma: Findings from an Australian Population
Elke Hacker et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure
Despina Handolias et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
Tailoring to RB: tumour suppressor status and therapeutic response
Erik S. Knudsen et al.
NATURE REVIEWS CANCER (2008)
Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma
Amira Sanki et al.
PATHOLOGY (2007)
Distinct clinical and pathological features are associated with the BRAF T1799A(V600E) mutation in primary melanoma
Wendy Liu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2007)
Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays
Mitchell Stark et al.
CANCER RESEARCH (2007)
Spontaneous and UV radiation-induced multiple metastatic melanomas in Cdk4R24C/R24C/TPras mice
E Hacker et al.
CANCER RESEARCH (2006)
Distinct sets of genetic alterations in melanoma
JA Curtin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence
SG Rane et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors
R Sotillo et al.
EMBO JOURNAL (2001)
Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice
P Krimpenfort et al.
NATURE (2001)
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis
NE Sharpless et al.
NATURE (2001)
Share Paper
